EUVIMEDEUVIMED entdecken
Crossref

Variation of tafamidis plasma levels during the treatment of TTR amyloidosis patients with Glu89Gln mutation

M Smerikarova, S Bozhanov, I Tournev, V Maslarska

European Journal of Clinical Pharmacology · 2023

DOI: 10.1007/s00228-023-03576-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Pharmacology, 2023. Verfasst von M Smerikarova und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Faculty of Pharmacy, Medical University, Sofia, 1000, Bulgaria. m.smerikarova@pharmfac.mu-sofia.bg. Hauptthemen laut MEDLINE: Prealbumin, Amyloid Neuropathies, Familial. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The transthyretin kinetic stabilizer tafamidis, used as a first-line therapy of amyloidosis patients, binds selectively to the transthyretin protein structure and thus prevents its dissociation. The limited information regarding tafamidis application in Glu89Gln amyloidosis patients imposed our research team to determine and evaluate its individual mean plasma levels and their biological variation. METHODS: The present cohort study investigated Bulgarian amyloidosis patients, grouped by gender, age, and therapy duration. A total of sixty patients aged 40-75 years and therapy duration up to 9 years were included. A precise and accurate high-performance liquid chromatography method with ultraviolet detection was used for plasma concentration measurement. RESULTS: Mean plasma concentrations were 5.13 ± 2.64 µmol/L and showed low intra-individual (18.50%) and high inter-individual variability (51.43%). No significant difference was observed between tafamidis plasma levels and therapy duration with p = 0.5941 (p < 0.05 considered significant), but a significant positive correlation was found between plasma concentration, gender, and age with obtained results about p-value 0.0001 and 0.0235, respectively. CONCLUSION: The summary results of the study showed differences that may be based on some specific clinical features of the Glu89Gln mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrealbuminAmyloid Neuropathies, FamilialHumansCohort StudiesMutationBenzoxazoles

Stichwörter der Autor:innen

BioanalysisGlu89GlnPlasma levelsRP-HPLCTafamidisVariation

Substanzen

PrealbumintafamidisBenzoxazoles

Autor:innen und Institutionen

  • Department of Chemistry, Faculty of Pharmacy, Medical University, Sofia, 1000, Bulgaria. m.smerikarova@pharmfac.mu-sofia.bg.
  • Department of Chemistry, Faculty of Pharmacy, Medical University, Sofia, 1000, Bulgaria.
  • Clinic of Nervous Diseases, Alexandrovska University Hospital, Medical University, Sofia, Bulgaria.

Zitieren

APA

Smerikarova, M., Bozhanov, S., Tournev, I., & Maslarska, V. (2023). Variation of tafamidis plasma levels during the treatment of TTR amyloidosis patients with Glu89Gln mutation. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-023-03576-3

Vancouver

Smerikarova M, Bozhanov S, Tournev I, Maslarska V. Variation of tafamidis plasma levels during the treatment of TTR amyloidosis patients with Glu89Gln mutation. European Journal of Clinical Pharmacology. 2023. doi:10.1007/s00228-023-03576-3

BibTeX
@article{Smerikarova2023,
  author = {Smerikarova, M and Bozhanov, S and Tournev, I and Maslarska, V},
  title = {Variation of tafamidis plasma levels during the treatment of TTR amyloidosis patients with Glu89Gln mutation},
  journal = {European Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1007/s00228-023-03576-3}
}
Kostenlos starten →